반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[CH:20]=[CH:19][C:18](Br)=[CH:17][CH:16]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[CH3:22][S:23]([C:26]1[CH:27]=[C:28]2[C:32](=[CH:33][CH:34]=1)[NH:31][CH2:30][CH2:29]2)(=[O:25])=[O:24]>>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[CH:20]=[CH:19][C:18]([N:31]3[C:32]4[C:28](=[CH:27][C:26]([S:23]([CH3:22])(=[O:25])=[O:24])=[CH:34][CH:33]=4)[CH2:29][CH2:30]3)=[CH:17][CH:16]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]참가 물질
3
실험 절차
The title compound was prepared by following the similar procedure as described in Intermediate-27 using tert-butyl-4-(4-bromophenoxy)piperidine-1-carboxylate and 5-(methylsulfonyl)indoline (0.11 g, 35%); MS: 373 (M−100).
출처 및 근거
- ORD 기록
- ord-4d6807a380ac49bb82f1befc55ad4d2a
- 출처 데이터셋
- uspto-grants-2015_04
- 특허 번호
- US09000175B2
연결된 노트
불러오는 중…